Alpine and AbbVie to develop, commercialize immunotherapy

By The Science Advisory Board staff writers

June 18, 2020 -- Alpine Immune Sciences and AbbVie have entered an exclusive worldwide option and license agreement for ALPN-101, a dual cluster of differentiation 28 (CD28) and inducible T-cell co-stimulator (ICOS) immune antagonist.

CD28 and ICOS are key immune modulators that play roles in multiple autoimmune and inflammatory diseases. ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways as demonstrated in multiple preclinical disease models.

Under the agreement, Alpine will receive an upfront payment of $60 million and will be eligible to receive development, regulatory, and commercial milestone payments of up to $805 million. Alpine will also be eligible for tiered royalties on net sales of ALPN-101. AbbVie will have the option to exclusively license ALPN-101.

Alpine will conduct a phase II clinical study in systemic lupus erythematosus. AbbVie will conduct all future clinical development, manufacturing, and commercialization for ALPN-101.

Thermo Fisher to develop, manufacture next-gen immunotherapy
Thermo Fisher Scientific has formed a strategic partnership with PharmAbcine for the development and manufacturing of PMC-309, a next-generation immune...
AbbVie licenses antibody technology for COVID-19
AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced that they have entered into a collaboration to develop a novel antibody...
AbbVie, Jacobio to collaborate on SHP2 inhibitors
AbbVie and Jacobio Pharmaceuticals announced they are partnering to develop and market SHP2 inhibitors, which target a node in cancer and immune cells.

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
BioProcess International Europe
July 13-17
Central European Time Zone (CET) Netherlands
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter